138 related articles for article (PubMed ID: 37103472)
1. Enhancing the Anti-tumor Potency of a Novel Siglec-15 Antibody by Engineering its Fc-mediated Effector Functions.
Ding H; Yao B; Ci L; Feng J; Ouyang P; Chen G; Hui X; Zhou D
J Immunother; 2023 Jun; 46(5):161-169. PubMed ID: 37103472
[TBL] [Abstract][Full Text] [Related]
2. Disruption of the sialic acid/Siglec-9 axis improves antibody-mediated neutrophil cytotoxicity towards tumor cells.
Lustig M; Chan C; Jansen JHM; Bräutigam M; Kölling MA; Gehlert CL; Baumann N; Mester S; Foss S; Andersen JT; Bastian L; Sondermann P; Peipp M; Burger R; Leusen JHW; Valerius T
Front Immunol; 2023; 14():1178817. PubMed ID: 37346044
[TBL] [Abstract][Full Text] [Related]
3. Siglecs-7/9 function as inhibitory immune checkpoints in vivo and can be targeted to enhance therapeutic antitumor immunity.
Ibarlucea-Benitez I; Weitzenfeld P; Smith P; Ravetch JV
Proc Natl Acad Sci U S A; 2021 Jun; 118(26):. PubMed ID: 34155121
[TBL] [Abstract][Full Text] [Related]
4. Patient-derived Siglec-6-targeting antibodies engineered for T-cell recruitment have potential therapeutic utility in chronic lymphocytic leukemia.
Cyr MG; Mhibik M; Qi J; Peng H; Chang J; Gaglione EM; Eik D; Herrick J; Venables T; Novick SJ; Courouble VV; Griffin PR; Wiestner A; Rader C
J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36442911
[TBL] [Abstract][Full Text] [Related]
5. Aptamer-Assisted Blockade of the Immune Suppressor Sialic Acid-Binding Immunoglobulin-Like Lectin-15 for Cancer Immunotherapy.
Wu Q; Wei X; Chen F; Huang M; Zhang S; Zhu L; Zhou L; Yang C; Song Y
Angew Chem Int Ed Engl; 2023 Dec; 62(52):e202312609. PubMed ID: 37955317
[TBL] [Abstract][Full Text] [Related]
6. Discovery of an agonistic Siglec-6 antibody that inhibits and reduces human mast cells.
Schanin J; Korver W; Brock EC; Leung J; Benet Z; Luu T; Chang K; Xu A; De Freitas N; Luehrsen K; Brehm MA; Wong A; Youngblood BA
Commun Biol; 2022 Nov; 5(1):1226. PubMed ID: 36369358
[TBL] [Abstract][Full Text] [Related]
7. Screening and Identification of a Novel Anti-Siglec-15 Human Antibody 3F1 and Relevant Antitumor Activity.
Wu J; Peng J; Zhou Y; Zhang R; Wang Z; Hu N; Zhang D; Quan G; Wu Y; Feng J; Shen B; Zhao J; Zhang Y; Yang K; Luo L
Mol Pharmacol; 2022 Sep; 102(3):161-171. PubMed ID: 35764384
[TBL] [Abstract][Full Text] [Related]
8. The sialoglycan-Siglec glyco-immune checkpoint - a target for improving innate and adaptive anti-cancer immunity.
Bärenwaldt A; Läubli H
Expert Opin Ther Targets; 2019 Oct; 23(10):839-853. PubMed ID: 31524529
[No Abstract] [Full Text] [Related]
9. Siglec-5 is an inhibitory immune checkpoint molecule for human T cells.
Vuchkovska A; Glanville DG; Scurti GM; Nishimura MI; White P; Ulijasz AT; Iwashima M
Immunology; 2022 Jun; 166(2):238-248. PubMed ID: 35290663
[TBL] [Abstract][Full Text] [Related]
10. SIGLEC-5/14 Inhibits CD11b/CD18 Integrin Activation and Neutrophil-Mediated Tumor Cell Cytotoxicity.
Bouti P; Blans C; Klein BJAM; Shome D; Nadafi R; Van Houdt M; Schornagel K; Verkuijlen PJJH; Roos V; Reijmers RM; Van Bruggen R; Kuijpers TW; Matlung HL
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38138970
[TBL] [Abstract][Full Text] [Related]
11. Siglec and anti-Siglec therapies.
Murugesan G; Weigle B; Crocker PR
Curr Opin Chem Biol; 2021 Jun; 62():34-42. PubMed ID: 33607404
[TBL] [Abstract][Full Text] [Related]
12. Characterization, pharmacokinetics, and pharmacodynamics of anti-Siglec-15 antibody and its potency for treating osteoporosis and as follow-up treatment after parathyroid hormone use.
Tsuda E; Fukuda C; Okada A; Karibe T; Hiruma Y; Takagi N; Isumi Y; Yamamoto T; Hasegawa T; Uehara S; Koide M; Udagawa N; Amizuka N; Kumakura S
Bone; 2022 Feb; 155():116241. PubMed ID: 34715394
[TBL] [Abstract][Full Text] [Related]
13. Development of Effective Siglec-9 Antibodies Against Cancer.
Wang JHS; Jiang N; Jain A; Lim J
Curr Oncol Rep; 2023 Jan; 25(1):41-49. PubMed ID: 36445569
[TBL] [Abstract][Full Text] [Related]
14. Targeting myeloid checkpoint Siglec-10 reactivates antitumor immunity and improves anti-programmed cell death 1 efficacy in gastric cancer.
Lv K; Sun M; Fang H; Wang J; Lin C; Liu H; Zhang H; Li H; He H; Gu Y; Li R; Shao F; Xu J
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 37935567
[TBL] [Abstract][Full Text] [Related]
15. Development of Siglec-9 Blocking Antibody to Enhance Anti-Tumor Immunity.
Choi H; Ho M; Adeniji OS; Giron L; Bordoloi D; Kulkarni AJ; Puchalt AP; Abdel-Mohsen M; Muthumani K
Front Oncol; 2021; 11():778989. PubMed ID: 34869028
[TBL] [Abstract][Full Text] [Related]
16. Long Noncoding RNA TUG1 Inhibits Tumor Progression through Regulating Siglec-15-Related Anti-Immune Activity in Hepatocellular Carcinoma.
Ren Y; Lyu J; Guo Y; Yao Y; Hu L
J Immunol Res; 2022; 2022():9557859. PubMed ID: 35237695
[TBL] [Abstract][Full Text] [Related]
17. Tumor cell-intrinsic and tumor microenvironmental conditions co-determine signaling by the glycoimmune checkpoint receptor Siglec-7.
van Houtum EJH; Kers-Rebel ED; Looman MW; Hooijberg E; Büll C; Granado D; Cornelissen LAM; Adema GJ
Cell Mol Life Sci; 2023 May; 80(6):169. PubMed ID: 37253806
[TBL] [Abstract][Full Text] [Related]
18. Siglec receptors as new immune checkpoints in cancer.
Stanczak MA; Läubli H
Mol Aspects Med; 2023 Apr; 90():101112. PubMed ID: 35948467
[TBL] [Abstract][Full Text] [Related]
19. Recent progress in targeting the sialylated glycan-SIGLEC axis in cancer immunotherapy.
Yu Y; Peng W
Cancer Biol Med; 2023 May; 20(5):369-84. PubMed ID: 37133224
[TBL] [Abstract][Full Text] [Related]
20. An Fc-Competent Anti-Human TIGIT Blocking Antibody Ociperlimab (BGB-A1217) Elicits Strong Immune Responses and Potent Anti-Tumor Efficacy in Pre-Clinical Models.
Chen X; Xue L; Ding X; Zhang J; Jiang L; Liu S; Hou H; Jiang B; Cheng L; Zhu Q; Zhang L; Zhou X; Ma J; Liu Q; Li Y; Ren Z; Jiang B; Song X; Song J; Jin W; Wei M; Shen Z; Liu X; Wang L; Li K; Zhang T
Front Immunol; 2022; 13():828319. PubMed ID: 35273608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
